Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
Shelby L. Merchant, PharmD, Kathryn Culos, PharmD, BCOP, and Houston Wyatt, PharmD, CSP
Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Houston Wyatt, PharmD, CSP, 1211 Medical Center Drive, Nashville, TN 37232. E-mail: email@example.com
J Adv Pract Oncol 2019;10(5):494–500 |
© 2019 Harborside™
There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies. Ivosidenib is the first approved oral, targeted, small-molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) mutation seen in AML. IDH1 mutations have been associated with significantly worse outcomes in disease-free survival, relapse-free survival, and overall survival (NCCN, 2018). This article reviews the clinical trials and dose escalation studies that led to the U.S. Food & Drug Administration approval for ivosidenib in patients with relapsed or refractory AML with a susceptible IDH1 mutation. Patient counseling and monitoring, including dosing and administration, are important steps that advanced practitioners should be aware of. The mechanism of action and pharmacokinetic information for ivosidenib is discussed, as well as recommendations for drug-drug interaction management. Adverse events and monitoring parameters are addressed in detail, as well as how to interrupt and resume treatment due to adverse events.
For access to the full length article, please sign in